Inavolisib for advanced pancreatic cancer after prior treatment
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a targeted drug called Inavolisib in people whose pancreatic cancer has worsened after earlier chemotherapy. The goal is to see if it can slow the cancer and what side effects might occur.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have pancreatic ductal adenocarcinoma that has grown after previous chemotherapy.
- You are 18 or older and have a tumor sample available for testing.
- You are able to perform daily activities with little or no help (ECOG score 0-1).
- Your blood counts and organ function (liver, kidneys, blood sugar) are within study limits.
- You agree to use effective birth control if there is any chance of pregnancy.
- You have not taken certain prior drugs like PI3K, AKT, mTOR, RAS, or BRCA inhibitors.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, IBI343, combined with chemotherapy for people with advanced pancreatic cancer that has gotten worse after first-line treatment. It looks at whether this combination can help shrink tumors or slow cancer growth.
This trial tests a combination of two targeted drugs (serplulimab and bevacizumab) plus two different chemotherapy regimens for people with advanced pancreatic cancer that has worsened after first-line treatment. The goal is to see if this new combination can help shrink tumors or slow the cancer.
This trial tests a new immunotherapy for people with advanced pancreatic cancer that cannot be removed by surgery or has spread. It may be an option if you have already tried at least one previous treatment or if you have not had any treatment yet, depending on the study group.
This trial tests a new immunotherapy drug (adebrelimab) combined with a standard chemotherapy cocktail (NALIRIFOX) for people with locally advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if this combination shrinks or controls the cancer better than chemo alone.
This trial tests inavolisib, a targeted cancer drug, in women with advanced or recurrent endometrial cancer that has a specific genetic mutation called PIK3CA. The drug is designed to stop cancer cells from growing by blocking a protein pathway that helps tumors survive.
This trial tests a new targeted therapy, inavolisib, combined with standard hormone therapy and a CDK4/6 inhibitor for people with a specific genetic mutation (PIK3CA) in their hormone receptor-positive, HER2-negative advanced breast cancer that has not been treated before. It compares this combination to a placebo plus the same standard treatments.
Hear when a new Pancreatic Ductal Adenocarcinoma (PDAC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.